中文摘要：

目的探讨S1RTl基因多态性与肺癌对以铂类为基础的化疗敏感性的关系。方法选取338名肺癌患者（其中184名对化疗耐药和154名对化疗敏感）为研究对象，所有患者均接受以铂类（顺铂、卡铂）为基础的化疗。分析其SIRTl的所有单核苷酸多态性，最后筛选出4个tagSNPs进行基因分型。OR和CI用来评估SIRTl基因多态性与肺癌患者化疗效果的相关性。结果在〉60岁的肺癌患者中，rs3758391的基因多态性与铂类化疗疗效显著相关（OR=0．38，P=0．049）。rs3740051、rsl2778366的遗传多态性与铂类化疗疗效之间无显著相关性。结论SIRTlrs3758391基因多态性可以显著影响肺癌患者铂类化疗的敏感性，SIRTl可能作为肺癌铂类化疗疗效评估的标志物。

英文摘要：

Objective To explore the relationship between the SIRT1 genetic polymorphisms and chemosensitivity to plati- num-based chemotherapy in lung cancer patients. Methods A total of 338 lung cancer patients （184 resistant and 154 sensitive） were selected and treated by platinum-based chemotherapy in this study. All single nucleotide polymorphisms in SIRT1 gene were analyzed and four tagging SNPs were finally screened for genotyped. The odds ratios （OIL） with 95 % confidence intervals （CI） were used to assess the effect of S1RT1 Genes Polymorphisms on the chemosensitivity of patients with lung cancer. Results We found a significant association of SIRT1 rs3758391 polymorphism with platinum-based chemotherapy effectiveness in lung cancer patients who were older than 60 years （OR=0.38, P = 0.049）. While no significant correlation was discovered between rs3740051, rs12778366 genetic polymorphism and platinum-based chemotherapy effect . Conclusion Our findings suggest that the SIRT1 rs3758391 genetic polymorphism can affect platinum-based chemotherapy sensitivity in lung cancer patients, and SIRT1 may be act as a potential biomarker on lung cancer chemotherapy response.